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Abstract 
 
 Some chemicals have a potential to initiate cancer by genetic alterations, such as by 
mutating nucleotides, and by changing the structure or number of chromosomes. 
Activity that causes these genetic alterations is defined as genotoxicity. Genotoxic 
compounds include agents that damage the DNA directly and indirectly. Different levels 
of concern need to be applied regarding the adverse effects of genotoxins in these two 
categories because the direct agents classified into clastogens have no safety threshold, 
while the indirect agents like aneugens have a threshold of exposure at which no toxic 
effect occurs. Therefore it is important to distinguish whether genotoxicity is 
clastogenic or aneugenic. Although a micronucleus test, the gold standard mammalian 
genotoxicity assay system, identifies both aneugens and clastogens, it cannot distinguish 
between the two types of activity.  
  Whether DNA damage exists or not is the most important information for 
discriminating between clastogens and aneugens; therefore this study proposed how to 
detect DNA damage using H2AX. Since H2AX can be induced not only by DNA 
damage but also by apoptosis, it was necessary to remove apoptotic H2AX from the 
analysis. Co-staining the cells with caspase-3 was tried as a method to identify the 
apoptotic cells. The result indicated that, whereas the elevated H2AX shown by a 
clastogen was caused by non-apoptotic cells, induction of H2AX by an aneugen was 
predominantly caused by apoptosis. The observation demonstrated that measurement of 
H2AX in caspase-3 positive and negative cells is a helpful method to classify aneugens 
and clastogens.  
 Next, the author tried to establish a new method of staining for immature red blood 
cells that could be used for flow cytometry (FCM) scoring of micronucleated cells in 
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the in vivo micronucleus test, which is commonly used to assess genotoxicity and in 
which an increase in micronucleated cells in immature erythrocytes suggests 
clastogenicity and/or aneugenicity. FCM can be used to estimate a reliable threshold of 
micronucleus induction because much greater numbers of sample cells can be analyzed 
than by standard microscopic observation. In order to identify immature erythrocytes 
with fluorescence suitable for use in FCM, two fluorescent dyes, Hoechst 33258 and 
propidium iodide were used. An appropriately adjusted concentration of Hoechst 33258 
and propidium iodide could provide clearly stained micronucleated immature 
erythrocytes. The method was also useful for erythrocytes from bone marrow samples 
with column purification of nucleic cells. Percentages of micronucleated immature 
erythrocytes or immature erythrocytes detected by FCM were similar to the values 
detected by microscopy. Two methods that use FCM to improve the throughput of data 
acquisition were established in this study, which will support assessment of the mode of 
action of genotoxic agents and derivation of an acceptable threshold. 
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Chapter 1. 
Introduction 
 
 
1.1 Genotoxicity and human health 
 Humans are exposed to a range of natural and artificial chemicals in their daily life. 
Some environmental chemicals that react with DNA or DNA-related components 
involved in replication and homeostasis of DNA may generate genetic alterations, 
including substitutions, deletions, or insertions in nucleotides and structural or 
numerical changes in chromosomes. Activity that induces genetic alterations is defined 
as genotoxicity. Cancer initiation by genetic alterations is recognized as the most 
important result of genotoxic effects. Carcinogenic activity is induced by long-time 
exposure of a human to a genotoxin. For example, bladder cancer was observed 
approximately 20 years after occupational exposure to ortho-toluidine commenced 
(Sorahan, 2008). Therefore, risk must be precisely assessed before people are exposed 
to genotoxins. An accumulation of DNA damage is also related to immune dysfunction 
and neurodegenerative diseases, and DNA damage in germ cells can cause spontaneous 
abortions, infertility, and genetic disease. Acceptable levels need to be set for chemicals 
used in various fields, including pesticide residue, pharmaceutical impurities, food 
additives, and occupational health. Genotoxicity assessment decides whether a chemical 
has a safety threshold or not.  
 This study focused on the development of new methods of genotoxicity assessment 
by which it is possible to set a threshold and understand the mode of action (MOA).  
 
1.2 Detection and control of genotoxic hazard 
 Mutations in oncogenes or tumor suppressor genes of somatic cells are known to 
2 
 
occur in cancer cells of humans and animals. A bacterial reverse mutation test (Ames 
test) detects the reverse mutations involved in the strains of Salmonella typhimurium (S. 
typhimurium) and Escherichia coli (E. coli), and can identify 90% of known 
carcinogens (Umbuzeiro et al., 2016). Clastogens induce structural chromosomal 
damage, including the deletion of part of the chromosome or transfer by DNA strand 
breaks (clastogenicity), and aneugens change the number of chromosomes 
(aneugenicity). Clastogens cause double-strand breaks (DSB) and single strand breaks 
(SSB). Some damage is lethal and some is repairable, but repairing error plays an 
important role in tumor initiation and progression. Aneugens induce the loss or gain of 
chromosomes during cell division and are associated with cancer development, and 
numerical changes of chromosomes have often been found in tumor cells (Fearon et al., 
1990; Aardema et al., 1998). Clastogens and aneugens can be detected with a 
chromosomal aberration (CA) test or a micronucleus test. The CA test and in vitro 
micronucleus test (MNvit) could predict 66%–79% of rat carcinogens (Kirkland et al., 
2005). 
 Combining tests with different endpoints increases the sensitivity and decreases the 
specificity of detecting carcinogens. In an ICH guideline that defines the approach for 
genotoxic assessment in pharmaceutical development, the standard in vitro test battery 
is defined as a combination of the Ames test and an in vitro mammalian cell assay, such 
as the CA test, the MNvit, or the mouse lymphoma forward mutation assay (MLA). 
Addition of an in vivo micronucleus test (MNviv) is required, because absorption, 
distribution, and metabolism of chemicals have important influences on the activity of 
chemicals. Because in vitro cytogenetic assays often generate positive results that are 
not relevant for human carcinogenicity, positive results are often confirmed by 
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follow-up tests. Kirkland et al. indicated that the Ames test combined with MNvit is 
sufficiently sensitive to detect rodent carcinogens (Kirkland et al., 2011). MNvit is an 
assay to measure the frequency of chromosomal damage by scoring micronucleated 
cells, which is a more simplified method than the CA test that directly observes all the 
chromosomes in each cell. Therefore, MNvit has become widely used for in vitro 
cytogenetic assessment. 
 
1.3 Genotoxic assay systems 
 To identify genotoxic potential, many assay systems have been proposed. In vitro 
systems are suited for identifying hazards due to their speed, low cost, frugal use of test 
article, and reduction of animal use. Combining some assay systems gives information 
about the genotoxic mechanism. Well-established genotoxicity assays are listed below 
and in Table 1-1. 
 
Bacterial reverse mutation test (Ames test)  
  The Ames test can detect gene mutations by scoring reverse mutation of bacteria.   
S. typhimurium and E. coli are used as tester strains. The S. typhimurium strain contains 
a base-pair substitution or frame-shift mutation in the histidine operon, and the E. coli 
strain also contains base-pair substitution in the tryptophan operon. Only the cells with 
reverse mutation can form colonies on a plate that lacks histidine or tryptophan.  
 
Mouse lymphoma forward mutation assay (MLA) 
 The MLA is an assay that detects gene mutations and chromosomal aberrations in 
mouse lymphoma cells by scoring drug-resistant colonies. Point mutations, deletions, 
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and chromosomal rearrangements make cells resistant to lethal nucleoside analogue 
trifluorothymidine. Small and large colonies indicate mutations in the chromosome and 
the gene, respectively. 
HPRT assay 
 The HPRT gene encodes the salvage pathway enzyme hypoxanthine-guanine 
phosphoribosyl transferase. The HRPT assay detects mutations that disrupt HPRT gene 
function. Mutant cells become resistant to a toxic analogue. When a mutation is caused 
at the hprt locus, cells become resistant to 6-thioguanine. Substitutions and small 
deletions of base pairs are detected using Chinese hamster ovary (CHO) cells, Chinese 
hamster lung (CHL) cells, or Chinese hamster V79 (V79) cells.  
 
Chromosomal aberrations test (CA test) 
 The CA test detects structural and numerical changes of chromosomes.  
Abnormal chromosomes in metaphase cells are scored by microscopy. In general, CHO 
cells, CHL cells, V79 cells, or TK6 cells are used.  
 
In vitro micronucleus test (MNvit) 
 The MNvit detects DNA fragments as micronuclei caused by chromosome break 
and abnormal distribution of chromosomes in dividing cells. Micronuclei are formed as 
extra-nuclear bodies through anaphase. DNA in nuclei and RNA in cytoplasm are 
stained with a nuclear staining reagent, then the micronucleated cells are scored. 
Micronucleated cells indicate both structural aberrations and numerical aberrations.  
 
In vivo micronucleus test (MNviv) 
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 DNA fragments and whole chromosomes form micronuclei in immature 
erythrocytes (IE). The MNviv evaluates micronucleus formation in bone marrow (BM) 
cells or peripheral blood (PB) cells of animals. Cells are stained with Giemsa or nuclear 
staining reagent, and the frequency of micronucleated cells is scored by microscopy or 
FCM.  
 
Mutation assay with transgenic rats and mice 
 In vivo gene mutations are analyzed using transgenic animals that possess a reporter 
gene (e.g. lacZ, lacI, gpt, red/gam) integrated into their chromosome. DNA is extracted 
from the tissue and transformed into E.coli. Mutation frequency is analyzed by counting 
colonies with a certain phenotype. 
 
Comet assay 
 The comet assay visualizes DSB and SSB in cultured cells or tissues. Cells in a 
layer of agarose on a slide are electrophoresed with a high-pH buffer. Small DNA 
fragments move to the anode faster than normal nuclei, so DNA fragments are seen by 
microscopy as having a comet tail.  
 
32
P postlabeling assay 
 A
 32
P-postlabeling assay detects DNA adducts by thin-layer chromato-graphy using 
32
P-labeled nucleotides  
 
SOS test 
 SOS genes (umuC, sfiA, recA, recN) are associated with the DNA repair system and 
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are expressed in bacteria following DNA damage and replication inhibition. An increase 
in the expression of SOS genes can be recognized by measuring the expression of a 
fusion protein that is located downstream of a SOS gene. 
 
Unscheduled DNA synthesis assay (UDS assay) 
 The UDS assay is used to count excision repair in rat primary liver cells by the 
intake of a labelled nucleoside as determined by autoradiography. DNA lesion repair 
occurs at each cell cycle stage, and DNA synthesis normally occurs in the S phase. 
Labelled nucleoside intake is recognized as an increase of DNA lesion. 
 
Erythrocyte-based Pig-a gene mutation assay (Pig-A assay) 
 The Pig-A assay detects a gene mutation by measuring decreased expression of a 
glycosylphosphatidyl inositol (GPI)-anchored cell surface protein. The 
phosphatidylinositol glycan complementation group A (Pig-a) gene is essential for the 
production of the GPI anchor that is needed for attaching proteins on the cell surface. 
Mutation of the Pig-a gene results in the loss of GPI-anchored proteins (e.g. CD59) on 
the surface of blood cells.  
 
1.4 Genotoxic MOA and setting the threshold  
 Genotoxins can be categorized as having either a DNA-reactive or a DNA 
non-reactive mechanism. The role of each class of genotoxin in carcinogenesis is 
indicated in Fig. 1-1 (Kirsch-Volders et al., 2003). DNA-reactive genotoxins cause 
DNA damage in a linear dose-dependent manner and can directly damage DNA even at 
low concentrations, so no threshold exists. This hypothesis is based on the concept that 
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a single mutation in critical genes, such as tumor suppressor genes or DNA damage 
response genes, could form cancer (Jenkins et al., 2010). DNA-reactive genotoxins 
include alkylating agents, N-nitroso compounds, and aflatoxins. Recently, a toxicologist 
has started a trial in which a cellular protective mechanism and the kinetics of blood 
concentration are taken into consideration when setting a safety threshold for 
DNA-reactive genotoxins; however, this trial has not been supported by sufficient 
evidence (Thomas et al., 2015). Therefore, compounds in this category basically cannot 
be developed as drugs for non-life-threatening diseases. A control strategy for 
DNA-reactive genotoxins is explained in the threshold of toxicological concern (TTC), 
which outlines the acceptable levels of lifetime cancer risk induced by very low levels 
of genotoxic compound, and it is considered to be less than 1/100,000 (Lovsin-Barle et 
al., 2016).  
 DNA non-reactive genotoxins damage DNA indirectly by inhibition of DNA 
synthesis, inhibition of spindle function, and generation of reactive oxygen species 
(Muller et al., 2000; Lynch et al., 2003). DNA non-reactive genotoxins are considered 
to have a safety threshold, because the function of a target protein can be maintained 
when some of the molecules are damaged. Spindle inhibitory activity, known as a type 
of aneugenicity, is classified in this category and indirectly contributes to genome 
instability and cancer. Treatment with an aneugen at a low concentration blocks mitosis 
and causes apoptosis, while at a high concentration, the aneugen causes abnormal 
chromosome segregation with tubulin crystallization (Guérard et al., 2015). Vinca 
alkaloids and taxanes are anticancer drugs that inhibit tubulin assembly or disassembly.  
 The existence of a safety threshold is important for the development of 
pharmaceuticals, because when the no observed adverse effect level (NOAEL) of a 
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compound is extremely higher than the effective concentration, development of the 
compound is allowed (Hernandez et al., 2009). Accordingly, classifying a compound as 
a clastogen or an aneugen is indispensable for setting a safety threshold. An overview of 
the thresholds for clastogens and aneugens is shown in Fig. 1-2. Both types of 
genotoxin form micronuclei by a different MOA.  
 To discriminate aneugens from clastogens, fluorescence in situ hybridization 
(FISH) is widely-used (Iarmarcovai, 2006; Attia, 2009). Cells in MNvit or MNviv are 
hybridized with kinetochores or centromeric DNA probes to know whether micronuclei 
have a kinetochore or a centromere or not. This method is time-consuming because 
micronucleated cells need to be searched and observed with two sets of filters, one for 
DNA and one for the probe.  
 Many of the positive results in in vitro genotoxicity tests using mammalian cells are 
considered to have no relation to human carcinogenicity. It was reported that at least 
80% of non-carcinogenic compounds gave positive results in at least one test among 
two or three of the in vitro genotoxicity tests (Kirkland, 2007). Some compounds are 
misclassified as genotoxic carcinogens because of conditions specific to the in vitro test, 
such as high cytotoxicity, inappropriate osmolality, and low pH. High cytotoxicity 
induces apoptotic cells with DNA fragments and cell-cycle perturbation, and low pH 
causes destabilization of DNA by the inhibition of protein synthesis (Morita et al., 1992; 
Meintières et al., 2004). The many false positives from in vitro mammalian assays 
means that follow-up tests to elucidate MOA and to consider human relevance are 
important when assessing genotoxic risk. 
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1.5 Application of FCM to genotoxicity assessment 
 A new drug requires 15–17 years of research and development. Non-clinical studies 
of efficacy, kinetics, compound characteristics, and safety take 5–7 years. Ten to thirty 
thousand chemicals are screened to obtain a drug candidate, but the success rate in 
creating a new drug is very low. Thus, high-throughput screening was focused on in the 
late 1990s as a valuable approach for accelerating each stage of development (Stark et 
al., 2016). Genotoxicity screening is conducted in the later stages of the pre-clinical 
phase, despite the fact that a positive result has a large impact on development. When 
genotoxic assessment shows a positive result, high-throughput analysis is needed to 
confirm the structure-activity relationship by analyzing many compounds. Rapid 
analysis of the relation between structure and positive activity is valuable for changing 
the chemical structure. 
 Currently, Pig-A assay and MNvit are considered as relatively high-throughput 
methods. The Pig-A assay uses FCM to detect erythroid cells and GPI-anchored 
proteins with fluorescent antibodies. The International Workshop on Genotoxicity 
Testing (IWGT) reported that the Pig-A assay may become a regulation study. However, 
this method is under construction and more validation studies are needed with various 
types of chemicals (Dobrovolsky et al., 2010).  
 FCM has been used to detect micronucleated cells especially in the MNviv (Torous 
et al., 2001; Dertinger et al., 2011). The ICH guideline S2 (R1) allows a pharmaceutical 
company to perform MNviv with imaging and FCM, and to integrate the study into a 
repeat-dose toxicology study. Integrating studies can reduce animal use because PB 
samples can be collected continuously without sacrificing the animal. Having various 
toxicology and toxicokinetics data from the same animal is also helpful for 
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understanding toxic effects. In BM samples, at least 4,000 cells are scored in each 
animal, and the total number of cells in one study is almost 140,000. When PB samples 
are used, the total number of scored cells is almost 700,000 cells (Lynch et al., 2011; 
OECD guideline 474). Microscopic observation in BM takes three people one month, 
and in PB takes longer.  
 Automated scoring using FCM is useful for higher throughput of analysis. 
MicroFlow® is a commercially available kit that is widely used in MNviv with PB 
samples. MicroFlow® uses RNase and PI for micronuclei and anti-CD71 antibody for 
IE. Platelets are distinguished from micronucleated IE (MIE) by staining with 
anti-CD61 antibody (Torous et al., 2000; Torous et al., 2001; Torous et al., 2003; Torous 
et al., 2005; Dertinger et al., 2004; Witt et al., 2008; Fiedler et al., 2010). The 
MicroFlow® kit is not suited as a screening tool, because it costs 400,000 yen/assay, 
and transferrin receptor (CD71) is not a specific marker of IE.  
 Acridine orange (AO) staining of micronucleated cells is also widely used. AO 
intercalates into a DNA double strand and binds to a RNA single strand; however, AO 
concentration and the number of cells cause an imbalance of specific staining. Criswell 
et al showed that AO staining can distinguish IE adequately, but the method identified 
micronucleated cells indirectly with forward angle scattering (Criswell et al., 1998; 
Criswell et al., 2003). Besides, AO stains the internal line tubing of a flow cytometer.  
 Other staining methods were also reported by Grawe et al. (Grawe et al., 1992; 
Grawe et al., 1997; Grawe et al., 1998; Grawe, 2005). This method used Hoechst 33342 
to detect DNA and thiazole orange to detect RNA. However, preparing the samples for 
this method was time-consuming.  
 In summary, the present FCM methods need to be further improved. The advantage 
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of analysis by FCM is that a large number of cells can be scored in a short time. 
Additionally, further information on the mechanism can be obtained by analyzing with 
biomarkers in FCM.  
 
1.6 Aim of the thesis 
 The aim of this study is to establish new systems for assessing the genotoxic MOA 
with FCM and to solve problems that arise in the current situation. This study attempts 
to 1) discriminate between clastogens and aneugens, 2) decrease the false positive rate 
in the in vitro genotoxicity assay and 3) improve the throughput of genotoxicity 
assessment. 
 
Study 1: Establishment of a new method to elucidate the MOA, clastogenicity, and 
aneugenicity using H2AX to detect DNA damage and caspase-3 staining to prevent 
false positives.       
 
Study 2: Establishment of a new method for the MNviv that is suitable for systems with 
much higher throughput. 
 
1.7 Outline of the thesis 
  The thesis is divided into four chapters. Chapter 1 gives an overview of the current 
standard of safety assessment and control of genotoxic chemicals. The study objectives 
include the aims of controlling genotoxic hazard and overcoming technical difficulties 
inherent in the traditional methods. Chapter 2 proposes a new method of distinguishing 
clastogens and aneugens that can support decisions made for the control strategy of a 
test compound based on threshold or non-threshold MOA. This study shows how to use 
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H2AX, a sensitive DNA damage marker, in genotoxicity assessment. Chapter 3 
describes the use of FCM in an in vivo micronucleus test. The ability of FCM to score 
numerous cells can provide better understanding of dose responses and much higher 
throughput than the widely used method of microscopic observation. In Chapter 4, this 
work is reviewed in a discussion of what was done, what can be improved, and its 
impact on genotoxicity assessment. 
 
1.8 General methods 
 
1.8.1 In vitro micronucleus test  
 MNvit is an attractive method because scoring is simple and the test can detect 
clastogens and aneugens. When a DNA fragment is caused by a chromosome break and 
abnormal distribution of the chromosome in dividing cells, extranuclear bodies are 
formed as micronuclei after the anaphase. The mechanism by which a micronucleated 
cell is formed is shown in Fig. 1-3. Chromosome damage by clastogens or chromosome 
non-disjunction by aneugens results in the formation of micronuclei in the interphase 
cells. Micronuclei represent a part of the chromosome or the whole chromosome with a 
kinetochore or centromere located outside the main nuclei. The size of micronuclei 
made from a whole chromosome is larger than those induced by a clastogen, but 
information on the size of micronuclei is not sufficient to distinguish the two types of 
genotoxin (Hashimoto et al., 2012). MNvit was established to detect chromosomal 
damage more easily than the CA test. The number of micronuclei is scored by 
microscopy after treatment with a test compound for 1.5 cell cycles. Cells are stained 
with a staining reagent, ;for example, with AO, Giemsa, or H33258 plus pyronin-Y. A 
micronuclei is defined as having a smaller diameter than a main nuclei. (Matsuoka et al., 
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1992). At least 2,000 cells are scored at each dose, and the total number of scored cells 
in one study is almost 32,000, so microscopic observation takes three people one week 
(OECD guideline 487). 
 It was reported that 69.2% of known non-carcinogens showed positive results in 
MNvit (Kirkland et al., 2005). In 1997, an OECD guideline recommended that the test 
condition needs to exceed 50% of cytotoxicity (OECD guideline 473). According to a 
discussion by the European Centre for the Validation of Alternative Methods (ECVAM) 
and IWGT, the OECD recommended in 2010 that the maximum concentration is based 
on 55±5% of cytotoxicity (Galloway et al., 2011; OECD Guideline 487), because 
experts consider that cytotoxicity is a major reason for a high ratio of false positives in 
the in vitro genotoxicity tests (Kirkland, 2007). Relative cell count (RCC), relative 
increase in cell count, and relative population doubling are mainly used in the 
micronucleus assays (Fowler et al., 2010). However, false positives in a highly 
cytotoxic condition have not been eliminated completely. 
 
1.8.2 In vivo micronucleus test 
 The MNviv in rodent BM or PB is one of a battery of studies used to assess 
genotoxicity. Rats are commonly used in toxicological studies and absorption, 
distribution, metabolism, and excretion (ADME) profiling of new drugs. Background 
knowledge and accumulated data in rats are helpful to understand the hazardous effect 
of test compounds. 
 Erythroblasts in bone marrow develop into IE after extruding the main nuclei. 
When DNA damage is caused in an erythroblast, a micronucleus is formed in the 
cytoplasm of an IE, which is then known as a MIE. Cytotoxicity is indicated as a 
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reduction in the population of IE. Newly formed IE are classified into types I-IV 
according to the RNA contents, and scored by staining of Giemsa or AO followed by 
microscopy or automated analysis. The frequency of micronucleated cells in PB is 15% 
that in the BM samples, because the spleen removes micronucleated cells from 
circulating blood (Schlegel et al., 1984). Therefore, micronucleated cells are easier to 
assess in a BM sample than in a PB sample. 
 
1.8.3 H2AX   
 Histone H2AX is one of the variants of the core proteins H2A, H2B, H3, and H4. 
Under normal conditions H2AX is phosphorylated on tyrosine (Y) 142. In survival cells 
Y142 is dephosphorylated by the tyrosine phosphatase, EYA. Serine (S) 139 of H2AX 
is phosphorylated in the presence of DSBs. Phosphorylated S139 becomes a binding site 
for DNA damage checkpoint protein MDC1, which is an adaptor protein that recruits 
the MRN (MRE11, RAD50, and NBS1) complex to S139. H2AX is mediated by ataxia 
telangiectasia mutated (ATM), ATM-Rad3-related (ATR), and DNA-dependent protein 
kinase (DNA-PK). Phosphorylated H2AX (H2AX) is rapidly accumulated at the site of 
a DSB to repair DNA damage. Therefore immunocytochemical detection with 
antibodies can visualize H2AX as a focus in a cell nuclei. H2AX is also formed by 
non-DSB damage. SSBs form DSBs via base excision repair, and a DNA cross-link 
forms DSBs via nucleotide excision repair (Takahashi et al., 2005). A comet assay can 
detect SSB and DSB in single cells, but H2AX detection of these types of damage by 
FCM is 100-times more sensitive than the comet assay (Kuo et al., 2008). DSB 
generation in normal cells is caused by V(D)J recombination of immune cells, DNA 
replication in the S phase cells, and DNA fragmentation of apoptotic cells.  
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Chapter 2. 
Evaluation of H2AX staining to distinguish clastogens and aneugens 
 
 
2.1 Introduction 
 Establishment of a new system to distinguish clastogens and aneugens was 
conducted using H2AX, in order to elucidate the MOA of genotoxic compounds. The 
results of common genotoxicity tests are judged qualitatively, but DNA non-reactive 
agents need a quantitative approach in order to control the amount of intake. Developing 
assay end-points that are quantitative is a valuable challenge. In this study H2AX was 
used in an alternative approach for MNvit. 
 When cells were treated with ionizing radiation, a correlation between the number 
of H2AX foci and DSBs in cells was shown (Ivashkevich et al., 2012); therefore, 
H2AX is considered to be a quantitative marker of genotoxicity assessment. As 
mentioned in Section 1.8.3, H2AX has the potential to be an attractive biomarker of 
DNA damage, but the evaluation criteria in a genotoxicity test have not been discussed.  
 In an experiment with UV radiation, H2AX was observed in both DNA lesions 
and pre-apoptotic signals (de Feraudy et al., 2010). H2AX in apoptotic cells shows a 
morphological feature with pan-nucleic staining, which differs from H2AX foci 
induced by DNA damage (Solier et al., 2009). Pan-nucleic H2AX is observed as high 
intensity cells with antibody staining, and Huang et al. showed that high intensity 
H2AX correlated with caspase-3 activation or chromatin condensation (Huang, 2004). 
In apoptotic cells, S139 and Y142 remain phosphorylated, and phosphorylated Y142 
inhibits the binding of MDC1 to S139. Recruiting c-Jun N-terminal kinase (JNK) and 
Fe65 to Y142 is also observed in apoptotic cells. Apoptosis gives rise to misleading 
judgments in both H2AX and MNvit. Identification of H2AX in apoptotic cells is 
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important to discuss the biological relevance of positive results. 
 Although p53 protein regulates cell cycle, apoptosis, and DNA repair, cells 
commonly used in MNvit (CHO, V79, and CHL) carry p53 mutations. Because 
p53-deficient cells cannot arrest cell cycle and cause only slight apoptosis after DNA 
damage, p53 status is one of the reasons why MNvit shows over-sensitivity and the 
results are biologically non-relevant for human risk. For this reason, human lymphoblast 
cells (TK6 cells) with the wild type of p53 status was chosen.  
 In this study, the DNA cross-linking agent mitomycin C (MMC) and the 
topoisomerase II inhibitor etoposide (ETP) were used as clastogens. A microtubule 
stabilizer, paclitaxel (PT), and the microtubule assembly inhibitor, vinblastine (VB), 
were used as aneugens. Previously, the DNA damage caused by PT and VB was 
considered to be biologically non-relevant: in the Ames test, PT and VB were negative 
(Ohno et al., 2008); in the CA test, VB showed numerical aberrations and no structural 
aberrations of chromosome (Matsushima et al., 1999); and in the comet assay, PT and 
VB showed a slight increase of the tail only at high cytotoxic concentrations (Lee et al., 
2003).  
 TK6 cells were stained with H2AX and the apoptotic biomarker caspase-3 after 
treatment with clastogens and aneugens. MNvit scoring by microscope and 
identification of aneugens by FISH analysis are time-consuming methods with 
individual differences due to the difficulties in finding and reproducing the appropriate 
condition for staining and washing the DNA probes. Antibody staining of H2AX is 
well adapted for detection by FCM analysis, which improves the throughput and results 
are more reliably reproducible. This study showed that the aneugens predominantly 
induced H2AX in apoptotic cells, while clastogens induced H2AX mainly in living 
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cells. In addition, the established system is more rapid than MNvit.   
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2.2 Materials and methods 
 
2.2.1 Cell culture and chemical treatment 
 TK6 cells were purchased from ATCC and cultured at 37ºC and 5% CO2 in 
RPMI-1640 medium (Gibco® Invitrogen, Carlsbad, CA) supplemented with 10% fetal 
bovine serum (Gibco® Invitrogen), 1 mM of sodium pyruvate (Gibco® Invitrogen), 100 
units/mL of penicillin-streptomycin (Gibco® Invitrogen), and 10 mM of 
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES, Gibco® Invitrogen). Cells 
were seeded at 1.3 x 10
6 
cells/3 mL/well into the culture plate (Corning Coster 3516, 
Corning NY), and then treated with the clastogens MMC (CAS RN 50-07-7; Kyowa 
Hakko, Tokyo, Japan) and ETP (CAS RN 33419-42-0; Sigma) and with the aneugens 
VB (CAS RN 143-67-9; Sigma, St. Louis, MO) and PT (CAS RN 33069-62-4; Sigma) 
for 24 h. After treatment, half of the cultured cells were washed and the number of cells 
was counted with a cell counter (KX-21, Sysmex, Kobe, Japan). The RCC of the treated 
cultures to the vehicle control was used as an indication of cytotoxicity.  
 
2.2.2 Fixation and staining of samples 
 Cells were fixed and permeabilized with 70% ethanol and stored at ￚ20ºC 
overnight. After being washed with PBS, cells were stained with anti-H2AX antibody 
(1:1,000, Anti-phospho-Histone H2A.X [Ser139], clone JBW301; Upstate 
Biotechnology, Lake Placid, NY) and anti-caspase-3 rabbit antibody (1:200, Cleaved 
Caspase-3 Asp175, Cell Signaling Technology Tokyo, Japan). Two secondary antibodies, 
anti-mouse antibody conjugated with R-Phycoerythrin (R-PE) (1:3,000, Polyclonal 
Goat Anti-Mouse Immunoglobulins, Dako Cytomation) for H2AX and anti-rabbit 
antibody with Alexa Fluor 488 (1:500, Polyclonal Goat anti-Rabbit Immunoglobulins, 
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Invitrogen) for caspase-3, were treated for 30 min at room temperature. The cells were 
washed and incubated with 20 g/mL of RNase and 1 g/mL of 4’, 
6-diamidino-2-phenylindole (DAPI) for 30 min.   
 
2.2.3 FCM scoring of cells 
 FCM settings for excitation wavelength were 488 nm (Alexa Fluor 488 and PE), 
and 355 nm (DAPI), and for the bandpass filter set were 530/30 nm (Alexa Fluor 488), 
575/25 nm (PE), and 450/50 (DAPI). The whole cell cycle was gated by DNA contents 
and analyzed for H2AX and activated caspase-3 from approximately 5,000 cells with 
FACSAria (BD Biosciences, San Jose, CA) and FlowJo 7.6.4 (TOMY Digital Biology 
Co., Ltd., Tokyo, Japan). Cellular H2AX was compared with the basal value of 5% in 
the vehicle control sample. Gating resulted in a beveled borderline to normalize per unit 
of DNA (Kurose et al., 2005). Caspase-3-positive or -negative cells and H2AX-bright 
or -dim cells were determined by the histogram of Alexa Fluor 488 or PE intensity. 
Chemicals were applied and cultured in duplicate, and the mean values of H2AX+ 
cells, caspase-3+ cells, H2AX+/caspase-3- cells, and H2AX+/caspase-3+ cells are 
shown in the results (Table 2-1). Statistical significance was determined by Fisher’s 
exact test.  
 
2.3 Results and discussion 
 
2.3.1 Images from microscopy and FCM analysis 
 Microscopic observation of H2AX and caspase-3 staining in the cells is shown in 
Fig. 2-1. R-PE (H2AX) and Alexa Fluor 488 (caspase-3) showed sufficient contrast to 
distinguish positive or negative cells. H2AX in H2AX+/caspase-3+ cells were seen 
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with brighter fluorescence by pan-nuclear staining. H2AX+/caspase-3- cells had 
H2AX foci in cells.  
2.3.2 Comparing H2AX (dim) cells and H2AX (bright) cells  
 The H2AX+ cells can be separated into H2AX (dim) and H2AX (bright) cells. 
H2AX (bright) cells were seen as isolated populations after treatment with aneugens 
(Fig. 2-2B). Fig. 2-2C shows representative FCM dot plots of MMC and PT at 59.5% 
and 55.2% of RCC, respectively. Although similar cytotoxicity was observed, PT 
induced caspase-3+ cells but there were few caspase-3+ cells in MMC. The dot plot of 
PT has a different shape from the control and MMC. After treatment with MMC, 
H2AX fluorescence was elevated, and cells in the dot plot shifted upwards. Treatment 
with ETP showed a similar response (not shown). In the cells treated with PT, H2AX+ 
cells also increased as compared to cells treated with vehicle and were of higher 
intensity than those treated with MMC. Treatment with VB showed a similar response 
(not shown).  
 Apoptotic cells showed pan-nuclear staining with high intensity of fluorescence 
with H2AX antibody (Huang et al., 2004; Solier et al., 2009). H2AX (bright) cells 
were regarded as pan-nuclear staining cells. When compared to H2AX positive cells 
(%) in caspase-3+/- and H2AX (bright)/(dim), aneugens increased 
H2AX+/caspase-3+ and H2AX (bright) cells considerably, but clastogens had low 
levels of these cell populations (Fig. 2-3). The number of H2AX+/caspase3+ double 
positive cells was higher than that of H2AX (bright) cells. At the highest concentration 
of each treatment,H2AX+/caspase-3+ and H2AX (bright) were 2.1% and 1.2% for 
ETP, 3.9% and 1.3% for MMC, 19.9% and 14.2% for PT, and 53.3% and 31.4% for VB, 
respectively. Yamamoto et al. showed that micronucleated cells were increased in both 
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TUNEL-positive and -negative cells with aneugens, whereas micronucleated cells 
induced by clastogens were TUNEL-negative (Yamamoto et al., 2014). The results of 
TUNEL and caspase-3 indicated that H2AX (bright) can be an apoptosis marker. 
However, not all the caspase-3+ cells were H2AX (bright). Pan-nuclear staining of 
H2AX was triggered by complex DNA lesions without DNA damage and apoptosis 
(Meyer et al., 2013). Accordingly, a high intensity of H2AX is not always shown in 
apoptotic cells. The level of H2AX is thought to depend on the progress of the 
apoptosis cascade. Thus, test chemical treatment duration and sampling time may affect 
the induction of H2AX (bright) cells in apoptosis. Therefore, caspase-3 is a more 
sensitive biomarker for apoptosis than H2AX (bright). 
 
2.3.3 Characteristics of H2AX+/caspase-3+ cells by clastogens and aneugens 
 H2AX+ cells increased significantly after treatment with all test compounds at 
various concentrations. The four compounds dose-dependently increased 
H2AX+/caspase-3+ and H2AX+/caspase-3- cells (Fig. 2-3A), and individual values 
are shown in Table 2-1. The experiments were performed within a range of slight to 
over 50% cytotoxicity. In the range of 50±10% RCC, H2AX+ cells increased 29.2% 
for MMC, 21.4% for ETP, 28.5% for PT, and 20.7% for VB. The vehicle control of 
H2AX+ cells ranged from 4.5% to 4.7%. 
 Caspase-3+ cells increased to 25.9% and 61.1% after treatment with PT or VB, 
respectively. Slight elevation of caspase-3+ cells was shown in a 
concentration-dependent manner, 4.9% for MMC and 2.9% for ETP. Laboratory 
background of caspase-3+ cells ranged from 0.4% to 2.1%.  
 H2AX+/caspase-3- cell percentages were calculated in order to know H2AX 
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induction of non-apoptotic cells. Vehicle controls ranged from 3.8% to 4.0%, and MMC 
and ETP markedly elevated H2AX+/caspase-3- cells to 38.4% and 37.5%, respectively. 
In the range of 50±10% RCC, H2AX+/caspase-3- cells were 27.5%, 19.3%, 8.6%, and 
7.2% after treatment with MMC, ETP, PT, and VB, respectively. Slight elevations the 
percentage of H2AX+/caspase-3- cells of PT and VB were outside the laboratory 
background (mean± SD; 3.9±0.4%, range; 2.6%–4.5%), but these values were not 
statistically significant (Table 2-1). VB showed only one positive response when RCC 
was 24.4%, which met the exclusion criteria proposed by Smart et al, who classified 
H2AX elevated above 25% RCC as a false positive (Smart et al., 2011). PT did not 
show a significant increase in those cells compared to vehicle control. 
H2AX+/caspase-3+ cell percentages to total cells indicated the impact of apoptosis on 
H2AX+ cell counts. In the range of 50±10% RCC, H2AX+/caspase-3+ cells were 
1.7%, 2.1%, 19.9%, and 13.4% with MMC, ETP, PT, and VB, respectively. PT and VB 
showed statistically significant increases of H2AX+/caspase-3+ cells compared with 
vehicle control. These results suggests that increased apoptotic cells resulted in H2AX 
induction after treatment with the aneugens. 
 
2.3.4 Comparison of H2AX/caspase-3 staining and FISH 
  Aneugen identification by the established method (H2AX-FCM) was compared 
with FISH using CH5164840, an inhibitor specific to heat-shock protein 90 (HSP90) 
(Matsuzaki, Harada et al., 2014). The analysis with H2AX-FCM showed that 
CH5164840 induced H2AX predominantly in apoptotic cells (Fig. 2-4). Eighty-five to 
ninety-four percent of micronucleated cells induced by CH5164840 treatment were 
centromere-positive. Centromere-positive micronucleated cells were 51% in the vehicle 
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control, and 50% with the clastogen, methylmethanesulfonate (Table 2-2). -tubulin 
staining of metaphase cells with indicated that CH5164840 induced asymmetric spindle 
formation (Fig. 2-5). These results suggest that CH5164840 is an aneugen. These results 
indicated that H2AX-FCM and FISH were equally valuable for distinguishing 
aneugens from clastogens. 
 
2.3.5 MOA of H2AX induction by clastogens and aneugens 
 The difference in H2AX induction after treatment with clastogens and aneugens is 
shown in Fig. 2-6. Caspase-activated DNA nuclease, phosphorylation of H2AX, and 
DNA degradation are caused in the downstream of caspase-3 activation (Trisciuoglio et 
al., 2009). Both DNA damage and spindle inhibitors trigger activation of caspase-3 and 
phosphorylation of H2AX, whereas microtubule damage or tubulin polymerization 
activated JNK, which consequently induced M phase cell cycle arrest (Brichese et al., 
2004; Chang et al., 2016). Activation of JNK is a primary stress signal of aneugens and 
is translocated into the nucleus to cause phosphorylation of H2AX. At the same time, 
the active form of JNK stimulates caspase-3 activation via the release of mitochondrial 
cytochrome c into the cytoplasm (Lu et al., 2006), and triggers DNA fragmentation and 
phosphorylation of H2AX in apoptotic cells (Cook et al., 2009; Baritaud et al., 2010). 
Additionally, H2AX of degraded DNA at the end of apoptosis showed low or negative 
levels of fluorescence (Fig. 2-2C). From the results of this study, activated JNK-related 
induction of H2AX has a limited impact compared with the mechanism related to DNA 
damage. 
 
2.4 Conclusions 
 Apoptotic cells contributed different levels of H2AX induction after treatment 
25 
 
with clastogens and aneugens. In the range of 50±10% RCC, the percentage of 
H2AX+/caspase-3- cells among total cells increased after treatment with clastogens, 
but not after treatment with aneugens. It is considered that JNK-related induction of 
H2AX by aneugens has a limited impact compared with clastogens. The results also 
suggested that aneugens did not induce DNA damage under the test conditions. High 
intensity of H2AX and increase of caspase-3+ cells were a feature of aneugen-treated 
cells.  Therefore, caspase-3 is a helpful marker to understand the MOA of 
H2AX-inducing agents.  
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Chapter 3. 
Detection of micronucleated cells in in vivo samples by FCM 
 
 
3.1 Introduction 
 The aim of this study is to create a method of simple fluorescent dye–based FCM 
(FD-FCM) for the MNviv. A widely accepted method is MicroFlow®, which is a 
CD71-based FCM assay, but MicroFlow® has limited applicability to PB samples and it 
is too expensive for repeated use. Fiedler et al. modified a protocol of MicroFlow® by 
purifying the erythrocytes of BM samples (Fiedler et al., 2010). Some experiments 
also tried to detect micronucleated cells by staining DNA and RNA with AO staining, or 
Hoechst 33342 and thiazole orange, but these methods were not well suited for 
detecting micronucleated cells by FCM (See Section 1.5). In this study, fluorescent dye 
was used in order to simply stain MIE and IE based on the mechanism that H33258 
binds to the A-T site in DNA and PI binds to A-T, A-U, and C-G sites in DNA and RNA 
(Fig. 3-1). Adjusting the concentrations of H33258 and PI made it possible to detect 
MIE, IE, and mature erythrocytes (ME) in blood and BM samples that were collected in 
rats after treatment with cyclophosphamide (CP). A clear contrast of DNA in 
micronucleated cells and RNA in IE was detected both with a microscope and by FCM. 
Remarkable correlations between FD-FCM and microscopic observation were obtained 
for MIE and IE. Therefore the established system has a better throughput and accuracy 
than conventional microscopic observation.  
 
3.2 Materials and methods 
 
3.2.1 Animals  
 Five RccHan
TM
:WIST rats (Japan Animal Laboratory Inc., Tokyo, Japan) of 7 
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weeks of age were orally dosed with cyclophosphamide monohydrate (CP, CAS RN 
6055-19-2, Sigma, St. Louis, MO) at a dose of 20 mg/kg/day for two days. Fifteen rats 
without any treatment were the negative control. This study was conducted in 
compliance with the institutional Guidelines for Animal Use and Care, which have 
AAALAC accreditation. 
 
3.2.2 Sample preparation 
 BM cells were collected from femora into fetal bovine serum containing 25 mM 
EDTA. After glass slide specimens were prepared for microscopic observation, 
nucleated cells in BM were removed by using a self-packed column (Romagna et al., 
1989; Frieauff et al., 1994). Briefly, equal weights of Sigmacell type 50 (Sigma) and 
alpha-cellulose (Sigma) were packed into a 2.5 mL plastic syringe, and erythrocytes 
were eluted with Hank’s Balanced Salt Solution. Eluted erythrocytes were re-suspended 
with 160 L of PBS and fixed with 2 mL of ultra-cold methanol.  
 BM samples with various percentages of MIE were mixed to analyze the detection 
range of FCM. The theoretical value of MIE was calculated based on microscopy scores. 
Prepared samples ranged from 0.23% to 4.89%.  
 PBs were collected by heparinized syringe, and a glass slide was prepared for 
microscopic observation using a portion of blood. PB was diluted into PBS and fixed 
with 2 mL of ultra-cold methanol (Torous et al., 2003). 
 
3.2.3 Staining of BM and PB cells 
 Aliquots of stored BM samples were centrifuged (600 x g, 5 min), and cells were 
suspended in a staining reagent (2.5 g/mL of H33258 (Sigma) and 0.25 g/mL of PI 
(Sigma)) for 30 min on ice. Then samples were washed with PBS and examined with a 
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flow cytometer (FACS Aria, BD Biosciences, San Jose, CA). Aliquots of stored PB 
samples were centrifuged, and cells were suspended in PBS for 30 min. Then, cells 
were stained in the same way as the BM samples. 
 
3.2.4 Scoring by FCM and microscopy 
 The samples were analyzed with FACSAria and FACSDiva software (BD 
Biosciences). FCM settings were as follows: excitation wavelength of 488 nm (PI), or 
355 nm (H33258), bandpass filter set at 660/20 nm (PI), or 450/50 nm (H33258). 
H33258-PI compensation was done so that IE and ME were positioned in a line. The 
PI-positive and PI-negative borderline was set by estimating it from a histogram. The 
upper limit of micronuclei was set as one third of the fluorescent intensity of nucleated 
cells (Fig. 3-2B and C). Microscopic observation was performed with AO (Sigma) 
staining, and 2,000 IE were observed (Hayashi et al., 1983).  
 
3.3 Results and discussion 
 
3.3.1 FCM analysis of H33258 and PI staining samples 
 PI binds to A-T, A-U, and C-G sites of DNA and RNA, and H33258 can bind to the 
A-T site of DNA. The concentration of H33258 was set 10 times higher than that of PI, 
to predominantly stain the A-T site. This simple staining led to clear fluorescence blue 
in DNA and red in RNA and provided sufficient contrast of IE, ME, and MIE. 
Microscopic observation of erythrocytes is shown in Fig. 3-2A. IEs were seen in red 
with PI staining at various intensities according to the content of RNA. MEs were not 
stained with PI. MIEs were stained blue at the micronuclei with H33258, and red at the 
cytoplasm with PI. Hydration of fixed cells was needed to obtain the appropriate 
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staining. 
 FCM dot plots are shown in Fig. 3-2B and C. Cells in the Q1 and Q3 compartments 
were classified as IE and ME, respectively. Nucleic cells were seen with high 
fluorescent intensity of H33258 in the Q2 compartment. PI- and H33258-double 
positive cells in the P2 compartment were MIE. A small number of nucleated cells 
remained after column purification. The upper limit of micronucleus size is usually 
defined as half the size of the main nuclei by microscopic observation (Matsuoka et al., 
1992). Consequently, the upper limit of micronucleus intensity of H33258 was set at 
one third the level of the nucleated cells. The value was calculated using (1/2)
3/2
 = 0.35 
to be adjusted for DNA amount.  
 
3.3.2 Reproducibility of MIE observation by FCM and microscopy 
 The reproducibility of FCM and microscopy was examined by scoring BM and PB 
samples ten times, and the results are shown in Fig. 3-3. Mean±SD and the CV of 
control BM were 0.18±0.06 and 32.8% by microscopy and 0.19±0.04 and 19.6% by 
FCM, respectively, while those of CP-treated BM were 6.52±0.82 and 12.6% by 
microscopy and 6.36±0.16 and 2.53% by FCM (Fig. 3-3A and B). The same values for 
control PB were 0.09±0.05 and 55.8% by microscopy and 0.19±0.06 and 30.8% by 
FCM, and those for CP-treated PB were 0.74±0.15 and 20.3% by microscopy and 
0.75±0.11 and 14.2% by FCM (Fig. 3-3C and D). The mean MIE% of ten repeated 
scorings was very similar by microscopy and FCM, and CV values with FCM in PB and 
BM were lower than those of microscopy. The CV by FCM was smaller than that by 
microscopy, because analysis was conducted for 20,000 cells in each sample by FCM 
and 2,000 cells by microscopy (Lynch et al., 2011). The results showed the reliability of 
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scoring by FD-FCM. When a sample contained MIE 0.74% in PB and 0.18% in BM by 
microscopy, the SD by FCM was similar to that of microscopy. PB samples found to 
have 0.09% of MIE by microscopy showed higher measurements by FCM. Better 
sensitivity or basal noise of FCM might affect the result. Precise comparing of the 
negative control was difficult because of very low levels of MIE; that is, 2/2,000 or less 
in 14/15 PB samples. 
 
3.3.3 Linearity of FD-FCM 
  BM samples with various percentages of MIE were scored with FCM to confirm 
the detection range of the measurements. Prepared samples contained MIE from 0.23% 
to 4.89%. Theoretical and measured values showed a correlation (r = 0.99) with a 
linear response (y = 0.96x) (Fig. 3-4). An inter-laboratory validation study by the 
Japanese Environmental Mutagen Society (JEMS) showed that the background level 
of MIE by microscopy was 0.07%±0.08% (mean ± SD) in rat PB, and 0.14%±0.12% 
in BM (Wakata et al., 1998). In another validation study, the mean MIE percentage for 
the negative control was 0.05% to 0.24% in PB, and 0.04% to 0.22% in BM by 
microscopy (Hayashi et al., 2007). Accordingly, 0.23% is the spontaneous level of 
MIE in rat PB and BM. FD-FCM showed linearity from the spontaneous level of MIE. 
 
3.3.4 Comparing FCM and microscopic analysis 
 The results scored by microscopy and FCM for MIE and IE in the same samples are 
shown in Table 3-1. The means of values scored by FCM for MIE in CP-treated PB and 
BM were 110% and 77% those observed by microscopy, and were 220% and 165% 
those in the control samples. MIE of negative control values were higher by FCM than 
by microscopy in this study. MicroFlow® also showed that the level of MIE found in 
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the negative control by FCM was higher than by microscopy (Torous et al., 2005; 
Fiedler et al., 2010). Therefore, the difference in MIE values measured by FCM and 
microscopy was considered to be acceptable. Linear approximations in the positive 
samples between microscopy and FCM were “MIE FCM = 1.07 x MIE microscopy, r = 
0.97” in PB, and “MIE FCM = 0.75 x MIE microscopy, r = 0.99” in BM.  
 Means for IE of CP-treated PB and BM scored by FCM were 74% and 94% those 
found by microscopic observation, and were 83% and 95% those in the control samples. 
MicroFlow® could score less than half of IE by microscopic scoring (Torous et al., 
2005), because expression of CD71 is specific to erythrocytes in the early maturation 
stage (Kono et al., 2009). Anti-CD71 antibody binds to 30%–50% of RNA-positive 
reticulocytes that correspond with the early stage of IE (Torous et al., 2003). Because 
RNA exists in all erythrocytes, FD-FCM could detect IE at similar values to those found 
by microscopy. Linear approximations in both control and positive samples between 
microscopy and FCM were “IE FCM = 0.80 x IE microscopy, r = 0.73” in PB, and “IE 
FCM = 0.94 x IE microscopy, r = 0.91” in BM.  
 
3.4 Conclusions 
  The results showed that H33258 and PI staining could clearly distinguish DNA in 
micronucleated cells and RNA in IE. FD-FCM provided reliable measurements of MIE 
and IE in rat BM and PB samples both treated with CP and solvent control. Linearity 
and reproducibility from the spontaneous level of MIE indicated that FD-FCM had 
practical reliability in MNviv. The simple procedure of FD-FCM can contribute to 
improve the throughput of MNviv. 
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Chapter 4. 
General conclusions 
 
 
4.1 General conclusions 
 The overwhelming advantage of FCM is its ability to score numerous cells quickly. 
A further advantage is that another biomarker can be easily added to an analysis to get 
information on the MOA of positive responses, for example, information on the cell 
cycle arrest, which tends to occur in the S phase with clastogens and in the M phase 
with aneugens. Also genotoxic signatures of DNA damage response are obtained by 
H2AX induction in each cell cycle (Smart 2011). Although image analysis is also 
available for these purposes, it is not easy for image analysis to score so many cells as 
FCM. In the literature of MN study followed by image analysis, our staining method 
scores 2,000 cells/sample (Shibai-Ogata et al., 2013), whereas 20,000 cells/sample were 
analysed with FD-FCM in this study. The sorting function, by which certain types of 
cells can be harvested for further analysis, is also an advantage of FCM. 
 Discrimination between clastogens and aneugens is important for the development 
of drugs, because control strategies for human health of the two agents is different. 
H2AX-FCM can be an alternative approach to FISH and gives a more rapid result than 
MNvit and FISH by microscopy.  
 H2AX was considered to be a new biomarker for a genotoxicity assay on account 
of its better sensitivity and its suitability to high-throughput screening. However, the 
methodology and positive criteria have not been established, and H2AX induction 
caused by apoptosis can cause a misleading assessment. A high ratio of false positives 
was also a problem of in vitro genotoxicity tests. Staining with caspase-3 can decrease 
false positives caused by apoptosis and elucidate the predominant expression of H2AX 
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in apoptotic cells with aneugens.  
 This study showed that FD-FCM could score MIE and ME of rat BM and PB 
samples by a simple technique. The problem of AO staining and MicroFlow® in MNviv 
was incorrect scoring of MIE and IE due to inadequate staining of the cells. An 
advantage of FD-FCM is the improved throughput and accuracy of scoring in the 
MNviv. Also, because the MNviv can be integrated into the in vivo general toxicity 
studies, it will reduce animal use. 
 Table 4-1 indicates the improved performance of the tests when using H2AX-FCM 
or FD-FCM as compared with traditional methods. Using the established analyses will 
improve throughput and provide greater accuracy than microscopy. Moreover, MNviv 
achieves considerable cost reduction.     
 
4.2 The usefulness of established methods  
 The author has already used H2AX-FCM to study the MOA of pharmaceutical 
candidates after positive results were obtained in the MNvit. It was proposed that the 
use of phosphorylated histone H3 (pH3) and polyploidy were valuable to identify 
aneugens (Cheung et al., 2015). Caspase-3 is not useful for apoptosis inducers, such as 
anti-FAS antibody, caffeine, or tributyltin. However, some kinase inhibitors did not 
achieve arrest of the cell cycle in the M phase (Mishima, 2017). Therefore, it would be 
useful to integrate caspase-3 and pH3 into a H2AX assay to understand the MOA of 
genotoxicity. In addition, other biomarkers can be used to elucidate the MOA of test 
compounds. 
  FD-FCM was designed to achieve a simple and high-throughput system for MNviv; 
however, this method is also helpful for understanding the MOA of genotoxic 
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compounds. Part of this method has already been used in some experiments by Takeiri 
et al. Micronucleated BM cells treated with the staining method of FD-FCM were 
harvested by a cell sorter, and concentrated samples of micronucleated cells were 
successfully analyzed for aneugens with FISH in rat in vivo (Takeiri, Harada et al., 
2013). Staining with H33258 and PI, sorting with FCM, and preparation of 
MIE-enriched slides overcomes the technical difficulty that micronucleated cells 
suitable for FISH analysis are too rare to provide a sufficient number from a few sample 
slides. To develop an automated system in MNvit for high-content screening, staining 
H33258 and PI was used (Shibai-Ogata et al., 2013). MIE and IE detection after 
treatment with MMC or VB was equally effective in both microscopic observation and 
imaging analysis. Whereas the commonly-used AO staining did not clearly distinguish 
IE from blood cells at a cytotoxic concentration in the imaging analysis because of the 
low RNA content, H33258 and PI staining could be applied to imaging analysis. 
 
4.3 Future perspective 
 H2AX-FCM and FD-FCM may change the use of genotoxicity screening from 
positive/negative selection to elucidating the MOA. When Ames-negative and 
micronucleus-positive results are obtained in the screening, it is difficult to know 
whether the positive result indicates a non-threshold MOA or not. Additionally, 
false-positive results sometimes occur in in vitro tests. Performing in vivo follow up 
tests is not a realistic way to confirm all the in vitro positives. Angiotensin-converting 
enzyme inhibitors and angiotensin II receptor antagonists are used for anti-hypertension 
therapy, but the cytotoxic effect of these compounds makes them positive in the in vitro 
genotoxicity test, and the anti-cancer agents, taxans and vinca alkaloids, also show 
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positive due to their aneugenic effect (Müller et al., 2000). Knowing the MOA in the 
early stage would be valuable for developing pharmaceuticals, and also the improved 
throughput achieved by this analysis method will be helpful to assess the 
structure-activity relationship of compounds. 
 Previously, genotoxicity assessment has been a qualitative assessment that can 
indicate only positive or negative results, but using FCM for H2AX with other 
parameters can provide mechanistic information. When a threshold MOA is suggested, 
the common strategy of deriving an acceptable exposure level based on the NOAEL 
detected in an in vivo study is useful. Due to its high scoring ability, FD-FCM can 
provide a more accurate NOAEL, and a combination of the two methods can provide 
helpful information to decide the control strategy of genotoxic compounds. Further, 
H2AX can be measured quantitatively by various methods, for example, FCM 
fluorescent intensity, masspectrometry, ELISA or focus counting. If quantitative H2AX 
data is accumulated, it may enable the relationship between exposure and DNA damage 
to be estimated, which would make it possible to find a compound-specific limit value, 
instead of the generic limit of 1.5 g/human/day for genotoxins with a direct MOA on 
DNA. 
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Table 1-1. Representative genotoxicity tests. 
 
 
In vitro  test In vivo  test
Ames test
Mouse lymphoma assay
HPRT assay
Chromosomal aberration test Chromosomal aberration test
Micronucleus test Micronucleus test
DNA adduct 32P-postlabeling assay
32
P-postlabeling assay
Rec assay
SOS assay
UDS assay
DNA strand break Comet assay Comet assay
UDS assay
Transgenic mouse/rat
Mutation assay
Gene mutation 
Chromosomal aberration
Indication assay DNA repair
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Table 2-1. H2AX and caspase-3 identification after treatment with clastogens and aneugens. 
 
1) Vehicle treatment. MMC, mitomycin C; ETP, etoposide; PT, paclitaxel; VB, vinblastine. 
0
 1) 100.0 4.6 1.1 3.8 0.8
3.1 92.5 9.9 1.4 8.9 1.0
6.3 87.3 13.9* 1.6 12.8* 1.2
12.5 76.8 20.3** 1.9 19.0** 1.4
25 59.5 29.2** 2.3 27.5** 1.7
50 44.9 42.3** 4.9 38.4** 3.9
0
 1) 100.0 4.5 1.0 3.8 0.7
4.7 96.7 5.2 1.1 4.7 0.5
9.4 88.5 6.9 1.2 6.1 0.8
18.8 74.1 10.2 1.4 9.2 1.0
37.5 55.6 21.4** 2.6 19.3** 2.1
75 35.1 39.6** 2.9 37.5** 2.1
0
 1) 100.0 4.5 1.2 4.0 0.5
1.3 98.9 4.5 1.6 3.4 1.1
2.5 90.3 7.1 3.9 4.4 2.8
5 67.4 23.7** 18.5** 9.4 14.4**
10 55.2 28.5** 25.9** 8.6 19.9**
20 33.0 27.9** 25.6** 7.9 19.9**
0
 1) 100.0 4.7 1.3 3.9 0.7
1.0 85.6 6.3 3.7 4.0 2.3
3.9 56.1 20.7** 18.7** 7.2 13.4**
15.6 39.6 26.5** 34.6** 4.4 22.1**
62.5 23.9 45.0** 49.5** 8.5 36.4**
250 24.4 68.1** 61.1** 14.8* 53.3**
H2AX+, cas3-/total (%) H2AX+, cas3+/total (%)
MMC
ETP
PT
VB
Compound Dose (ng/mL) RCC (%) H2AX+/total (%) Cas3+/total (%)
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* p<0.05, ** p<0.01, Fisher’s exact test. 
 
Table 2-2. FISH analysis of HSP90 inhibitor. 
 
 
(Matsuzaki, Harada et al., 2014) 
 
  
Dose RCC
(g/mL) (%) CMN (%) 
b) /
DMSO － 100 2.0 0.9 51 / 49 9.2 8.8 1.3
0.1 63 1.3 2.4 * 85 / 15 * 40.8 * 7.2 2.5 *
CH5164840 0.3 52 1.0 5.4 * # 93 / 7 * # 100.4 * # 7.6 5.5 * #
0.5 51 1.0 5.0 * 94 / 6 * 94.0 * 6.0 6.2 *
MMS 15 45 0.8 4.2 * 50 / 50 42.0 * 42.0 * 2.2
Abbreviations: relative cell count, RCC; population doubling, PD; micronuclei, MN; centromere-positive MN, CMN; non-centromeric MN, NMN; dimethyl sulfoxide, DMSO; 
methylmethanesulfonate, MMS.
The value of each dose was the mean of the value with duplicate culture well.
1) Calculated from  MN cells (%) [a] and CMN (%) [b] at each treatment; CMN = 2000×a/100×b/100, NMN =2000×a/100-CMN
* p < 0.01  Chi-square test
# p < 0.01  Cochran-Armitage trend test
Mitotic cells (%)PDCompounds
FISH analysis on  MN Frequency/2000 cells 
1)
CMN cells NMN cells
MN cells (%) 
a)
 NMN (%)
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Table 3-1. MIE and IE scores from microscopy and FCM. 
 
 
CP, Cyclophosphamide. 2,000 IE in BM, and 20,000 IE in PB per animal were examined. 
 
 
Animal No. Microscopy FCM
FCM /Microscopy
(%)
Microscopy FCM
FCM /Microscopy
(%)
Microscopy FCM
FCM /Microscopy
(%)
Microscopy FCM
FCM /Microscopy
(%)
1 64.1 59.5 93 0.20 0.26 130 4.90 3.07 63 0.05 0.25 500
2 53.9 51.0 95 0.15 0.20 133 3.56 4.35 122 0.05 0.13 260
3 54.5 50.0 92 0.30 0.32 107 4.10 4.86 119 0.10 0.06 60
4 52.9 53.0 100 0.15 0.17 113 4.28 4.79 112 0.00 0.09 -
5 52.4 51.1 98 0.05 0.28 560 5.99 5.08 85 0.00 0.10 -
6 38.7 41.4 107 0.20 0.24 120 4.26 3.98 93 0.05 0.12 240
7 44.6 37.9 85 0.15 0.26 173 6.46 3.45 53 0.15 0.13 87
8 57.1 50.4 88 0.10 0.29 290 5.38 5.50 102 0.05 0.07 140
9 35.8 37.5 105 0.20 0.34 170 4.53 5.02 111 0.05 0.08 160
10 58.4 51.8 89 0.05 0.38 760 6.60 4.62 70 0.10 0.12 120
11 53.2 49.4 93 0.20 0.42 210 5.73 4.10 72 0.05 0.08 160
12 58.0 60.7 105 0.30 0.36 120 3.77 3.48 92 0.05 0.09 180
13 53.7 47.3 88 0.20 0.21 105 5.96 2.89 48 0.05 0.09 180
14 51.5 47.4 92 0.10 0.25 250 6.35 4.37 69 0.00 0.14 -
15 43.2 43.4 100 0.25 0.23 92 4.79 4.34 91 0.00 0.06 -
Mean 51.5 48.8 95 0.17 0.28 165 5.11 4.26 83 0.05 0.11 220
SD 7.71 6.72 0.08 0.07 1.02 0.77 0.04 0.05
16 43.0 43.3 101 4.60 3.77 82 2.25 1.14 51 0.90 1.13 126
17 37.9 32.2 85 5.05 4.04 80 1.77 2.24 127 1.25 0.91 73
18 37.9 29.0 77 5.30 4.58 86 1.90 0.94 49 1.05 1.42 135
19 34.4 36.3 106 8.60 5.69 66 1.99 1.67 84 2.00 2.06 103
20 38.2 39.4 103 4.45 3.42 77 1.57 1.03 66 1.00 1.32 132
Mean 38.3 36.0 94 5.60 4.30 77 1.90 1.40 74 1.24 1.37 110
SD 3.08 5.68 1.71 0.89 0.25 0.55 0.44 0.43
BM
IE% MIE%
PB
MIE%IE%
Control
CP
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Table 4-1. A comparison of the performance of micronucleus tests. 
 
 
FCM, flow cytometry; HCS, high-content screening; FISH, fluorescence in situ hybridization. 
  
Method Microscopy H2AX-FCM Microscopy FD-FCM
Scoring time/person/test 3-week 1-hour 3-months 3-hours
Cost/test ¥5,000 ¥5,000 ¥400,000 ¥4,000
MOA - possible - possible
Application microscope
FCM
HCS
microscope
FCM
FCM
HCS
FISH
Accuracy - improved - improved
MNvit MNviv
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Figure 1-1. The process of carcinogenesis by DNA-reactive and DNA non-reactive 
genotoxins. 
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Figure 1-2. Linear and non-linear dose-response of DNA-reactive and DNA 
non-reactive genotoxins. 
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Figure 1-3. Representation of micronucleus formation by clastogens and aneugens. 
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Figure 2-1. Microscopic images of cells stained with caspase-3+/- and H2AX+/-. 
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Figure 
2-2. Flow cytometry analysis of TK6 cells treated with a clastogen and as aneugen. 
(A) Caspase-3+/- cell criteria were set using a histogram of Alexa Fluor 488 intensity. (B) H2AX 
(bright)/H2AX (dim) populations were separated by histograms of PE intensity. (C) The H2AX+ 
gate was set at 5% of H2AX+ cells in vehicle control. The bottom gate was set obliquely to adjust 
DNA content.  
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Figure 2-3. Induction of H2AX and caspase-3 in TK6 cells. 
(A) H2AX+/caspase-3+ (dark shading) and H2AX+/caspase-3- (light shading) (B) H2AX (bright) 
(dark shading) and H2AX (dim) (light shading). 
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Figure 2-4. H2AX/caspase-3 analysis of TK6 cells treated with a HSP90 inhibitor.  
(A) Induction of micronuclei (filled circles), cytotoxicity (open triangles), and HSP70 (columns). 
HSP70 indicates inhibition of HSP90 (light shading) and in (B) of H2AX+/caspase-3+ (dark 
shading), H2AX+/caspase-3- (light shading). 
(Matsuzaki, Harada et al., 2014) 
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Figure 2-5. -Tubulin staining of TK6 cells treated with an HSP90 inhibitor. 
(Matsuzaki, Harada et al., 2014) 
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Figure 2-6. H2AX induction cascade by a clastogen and an aneugen. 
ATM; ataxia telangiectasia mutated, DNA-PK; DNA-dependent protein kinase, CAD; 
caspase-activated DNAse, JNK; c-jun N-terminal kinase.  
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Figure 3-1. H33258 and PI staining mechanism. 
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Figure 3-2. H33258 and PI staining in BM cells. 
(A) Microscopic observation, (B) FCM analysis of a negative sample and (C) FCM analysis of a 
positive sample. Q1: IE, Q2: Nucleated cells, Q3: ME, P2: MIE. 
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Figure 3-3. Repeated analyses of MIE with microscopy and FCM. 
(A) Non-treated BM, (B) CP-treated BM, (C) Non-treated PB, (D) CP-treated PB. 
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Figure 3-4. Linear response of FCM scoring in BM cells. 
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